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Plant expression of cocaine hydrolase-Fc
fusion protein for treatment of cocaine
abuse
Guojun Wang1,2,4, Ting Zhang1,2, Haifeng Huang1,2, Shurong Hou2, Xiabin Chen1,2, Fang Zheng1,2*
and Chang-Guo Zhan1,2,3*

Abstract
Background: A recently reported cocaine hydrolase (CocH3) fused with fragment crystallizable (Fc) region of
human immunoglobulin G1, denoted as CocH3-Fc, is known as a promising therapeutic candidate for the
treatment of cocaine overdose and addiction. A challenge for practical therapeutic use of this enzyme
exists in the large-scale protein production and, therefore, it is interesting to identify a low-cost and
feasible, sustainable source of CocH3-Fc production.
Results: CocH3-Fc was transiently expressed in plant Nicotiana benthamiana leaves. The plant-expressed
protein, denoted as pCocH3-Fc, was as active as that expressed in mammalian cells both in vitro and
in vivo. However, compared to the mammalian-cell expressed CocH3-Fc protein, pCocH3-Fc had a shorter
biological half-life, probably due to the lack of protein sialylation in plant. Nevertheless, the in vivo half-life
was significantly extended upon the PEGylation of pCocH3-Fc. The Fc fusion did not prolong the biological
half-life of the plant-expressed enzyme pCocH3-Fc, but increased the yield of the enzyme expression in the
plant under the same experimental conditions.
Conclusions: It is feasible to express pCocH3-Fc in plants. Further studies on the pCocH3-Fc production in
plants should focus on the development of vectors with additional genes/promoters for the complete protein
sialylation and for a better yield.
Keywords: Therapeutic protein, Fusion protein, Protein production, Drug abuse

Background
Cocaine is the most reinforcing drug in stimulating the
reward pathway of the brain and teaching the user to
take it again [6, 13, 15]. Despite decades of effort,
classical pharmacological approaches to antagonizing
neuropharmacological actions of cocaine has not proven
successful, because it would be extremely difficult to
antagonize its physiological effects without affecting
normal functions of central nervous system (CNS) [29].
The inherent difficulties of antagonizing cocaine in the
CNS led to the development of protein-based therapeutic agents that can tightly bind with cocaine and,
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thus, prevent cocaine from reaching the CNS or accelerate cocaine metabolism [21, 29]. In particular, the
pharmacokinetic approach with an efficient cocainemetabolizing enzyme is recognized as the most promising treatment strategy for cocaine overdose and
addiction [2, 5, 20, 29]. Unlike the stoichiometric
binding of an antibody with drug, one enzyme molecule
can degrade multiple drug molecules, and the efficacy
of an enzyme is dependent on its catalytic rate constant
(kcat) and Michaelis-Menten constant (KM) against the
drug.
The principal metabolic enzyme of cocaine in human
body is butyrylcholinesterase (BChE) in the plasma,
producing biologically inactive metabolites. However,
the catalytic efficiency (kcat/KM) of wild-type human
BChE against naturally occurring (−)-cocaine is too
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low (kcat = 4.1 min−1 and KM = 4.5 μM) [22] to be effective
for (−)-cocaine metabolism. Below we will always refer
cocaine to (−)-cocaine, unless explicitly stated otherwise,
for convenience. In previous studies, we successfully
designed and discovered human BChE mutants with at
least 1000-fold improved catalytic efficiency against
cocaine compared to wild-type human BChE, and these
BChE mutants are recognized as true cocaine hydrolases
(CocHs) in literature [2, 17, 25, 27, 28]. The first one of
our designed CocHs, known as CocH1 (A199S/S287G/
A328W/Y332G mutant of human BChE) [17, 26], was
fused with human serum albumin (HSA) to improve the
in vivo stability [2], and the obtained HSA-fused CocH1 is
also known as Albu-CocH, Albu-CocH1, AlbuBChE, or
TV-1380 in literature [2, 5, 20, 23]. Clinical trials demonstrated that TV-1380 is safe and effective for use in
animals and humans ([5, 20]). TV-1380 has a biological
half-life of ~8 h in rats [2] and 43–77 h in humans [5].
However, its actual therapeutic value for cocaine addiction
treatment is still limited by the relatively lower catalytic
activity of TV-1380 against cocaine compared to the more
recently reported human BChE mutants, and the costs for
large-scale protein production. The lower the catalytic
activity of the enzyme against cocaine, the higher the
required dose of the enzyme, and thus the higher the costs
would be.
Notably, our more recently reported A199S/F227A/
S287G/A328W/Y332G mutant of human BChE, known
as CocH3 [24, 28], is significantly more active against
cocaine compared to CocH1. Further, we have recently
designed, prepared, and tested a long-acting form of
CocH3, denoted as CocH3-Fc [4], a fusion protein in
which the C-terminus of CocH3 is fused with the Nterminus of fragment crystallizable (Fc) region of human
immunoglobulin G1 (IgG1). The CocH3-Fc protein
expressed in Chinese hamster ovary (CHO) cells may be
regarded as a catalytic antibody analog, because it is as
active as the unfused CocH3 against cocaine with a
considerably longer biological half-life (e.g. t1/2 = ~107 h
in rats) like an antibody [4]. A single dose of CocH3-Fc
was able to block cocaine-induced hyperactivity and
toxicity for a long period [4].
On the other hand, it has been very challenging to
express BChE and its mutants in a commercially feasible
expression platform. For example, the low yield of
protein expression in CHO cells equates with high costs
for protein production and ultimately treatment. It is
highly desired to identify a low-cost and feasible,
sustainable source of CocH3-Fc production for practical
application of CocH3-Fc-based enzyme therapy. Generally speaking, rapid, transient expression of a foreign
protein in plant is readily scalable for large-scale production with low costs [7, 8]. Interestingly, Mor et al. have
demonstrated that plant can serve as an expression host
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for wild-type BChE [7, 8] and its mutants [9, 14]. It has
also been known that the plant-expressed BChE (pBChE)
or a pBChE mutant has a relatively shorter half-life
compared to the same protein expressed in CHO cells
due to the lack of complete polysialylation during the
post-translational modification (glycosylation) in plant.
Nevertheless, co-expression of pBChE with additional
genes required for in planta protein sialylation can
produce the desired pBChE with the overall glycosylation
profile resembling the plasma-derived orthologue in order
to have a much longer biological half-life [19].
The above background shows that plant protein
expression is a truly valuable source of protein production for human BChE and its mutants (including CocH3)
for practical use. However, it is unknown whether our
most recently designed catalytic antibody analog CocH3Fc [4], an Fc-fusion protein, can also be expressed in a
plant. We are particularly interested in the Fc-fusion
protein, because Fc portion of the fusion protein lends
itself to easier purification using conventional protein A
chromatography, potentially reducing the number of
processing steps in the manufacture of CocH3-Fc at large
scale. We also wanted to know whether pCocH3-Fc
expressed in a plant has a significantly longer biological
half-life than the unfused protein pCocH3 expressed in
the same plant. Here we report the establishment of a
Nicotiana benthamiana plant expression system for the
production of pCocH3-Fc. In comparison with the
unfused pCocH3, pCocH3-Fc can be expressed more
efficiently under the same experimental conditions. This is
the first report of a heterologous expression of an Fc-fused
cocaine hydrolase or BChE or BChE mutant in plants.

Methods
Constructions for plant expression

Starting from the sequences of human BChE (accession
number P06276 in the Swiss Protein Database), the
CocH3 or CocH3-Fc cDNA was first subjected to codon
optimization according to codon bias of N. benthamiana, and then cloned via Gateway (Invitrogen) cloning technology into the vector pSITE0A, a member of
pSITE family Agrobacterium binary vectors developed by
Dr. Goodin for the purpose of protein expression in
plant [3]. As illustrated in Fig. 1, various constructions
with or without a signal peptide, with or without fusion
with Fc fragment were prepared via different combinations of corresponding primers: the coding sequences
of amino acids 1–529 of the CocH3 were amplified with
pfu DNA polymerase (Stratagene, La Jolla, CA) by using
corresponding templates harboring point mutations
A199S/F227A/S287G/A328W/Y332G on human BChE
(stocked in this lab) with a forward primer 12-7_F_ENTR
(for constructs without N-terminal signal peptide) or
12-7_F_sig_ENTR (for constructions with N-terminal
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Fig. 1 Diagram of constructs used in this study. CocH3: 1–529
amino acids of CocH3. Fc: Fc region of human IgG1. N-terminal
ER-targeted signal: MDSKVTIICIRFLFWFLLLCMLIGKSHT. ER-retention
signal: SEKDEL. Promoter: Cauliflower mosaic virus (CaMV) 35S
promoter from pRTL2-GUS. Terminator: CaMV 35S terminator
from pRTL2-GUS

signal peptide) and a reverse primer 12-7_R (for constructions without C-terminal signal peptide) or 12-7_R_sig
(for constructions with C-terminal signal peptide). The Fc
fragment was amplified by using a forward primer FC_F
and a reverse primer FC_R_ENTR (for constructions
without C-terminal signal peptide) or FC_R_sig _ENTR
(for constructions with C-terminal signal peptide). All of
the primers used are listed in Table 1. The CocH3-Fc
fusion PCR was done based on 12 bp nucleotide
sequences overlapping the 3’-end of CocH3 gene and
5’-end of Fc fragment, followed by a full-length PCR
using a CocH3 forward primer and an Fc reverse primer.
The promoter and terminator used are the cauliflower
mosaic virus (CaMV) 35S promoter and the CaMV 35S
terminator, respectively, from pRTL2-GUS [18].
Transient transfection of N. benthamiana with pCocH3 or
pCocH3-Fc expression constructs

N. benthamiana wild-type plants used in this study were
maintained by Dr. Michael Goodin’s lab in the College
of Agriculture Greenhouse operations and facility at the
University of Kentucky. The College of Agriculture
Greenhouse operations and facility is administered by
Facilities Management of the university. Young N.

Table 1 Primers used in this study
Primer

Sequence

12-7_F_ENTR

5′-CACCATGGAAGATGACATCATAATTGCAACA-3′

12-7_F_sig_ENTR 5′-CACCATGGATAGCAAAGTCACAATCATATG-3′
12-7_R

5′- ATAGAGCTCTTAGACTTTTGGAAAAAATGATGTCCAG-3′

12-7_R_sig

5′-ATTTCAGAGTTCATCCTTCTCAGAGAGACCCACACA
ACTTTCTTTCT-3′

FC_F

5′-TTCCAAAAGTCGTGGAGCCTAAGTCCTGCGACAA-3′

FC_R_ENTR

5′-ATTTTTACCCGGAGACAGGGAGAG-3′

FC_R_sig _ENTR

5′-ATTTCAGAGTTCATCCTTCTCAGATTTACCCGGAGACA
GGGAGAG-3′
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benthamiana plants with 4–5 true leaves were used for
protein expression in this study. Expression plasmids
(see Fig. 1) were transformed into Agrobacterium tumefaciens strain GV3850 following the standard freezethaw method [10]. After confirming the presence of
plasmid by clone PCR, A. tumefaciens strains were cultured for overnight in 5 mL of LB media supplemented
with spectinomycin (100 μg/mL), rifampicin (100 μg/mL),
and streptomycin (20 μg/mL) on a shaker (200 rpm)
at 28 °C, which by a ratio of 1:100 was transferred to
fresh YEP medium (http://cshprotocols.cshlp.org/) supplemented with the same antibiotics. After OD600 reached
~0.7, Agrobacterium cells were collected by centrifugation
at 4000 × g for 15 min at 4 °C, washed twice by using MES
buffer (10 mM MgCl2, 10 mM MES, pH 5.6), and
re-suspended in the MES buffer supplemented with
200 μM acetosyringone to OD600 = ~0.7. The cell suspension was kept at room temperature for 2–3 h, and then
used to infiltrate plant leaves by vacuum infiltration. After
keeping infiltrated plants in dark overnight, plants were
cultured under light (14 h per day) at room temperature.
Unless stated specifically otherwise, leaves were harvested
at 3 days after infiltration, and immediately frozen in
liquid nitrogen and kept at −80 °C for use in subsequent
experiments.

Protein extraction and purification

For small scale, leaves were grounded in liquid nitrogen
to fine powder which was re-suspended in 100 mM
phosphate buffer (PB) (pH 7.4) supplemented with
protease inhibitor cocktail (ordered from Sigma) with a
ratio of 3 mL buffer per gram leaves. For large scale,
leaves were grounded by a blender (Oster) in the presence
of cold PB buffer supplemented with the same protease
inhibitor cocktail. For better plant cell lysis, the grounded
leaf mixture was passed through a French Press (Thermo
Scientific). After centrifuging at 23,000 × g for 15 min at
4 °C, the supernatant, after filtration through Miracloth
(EMD Millipore), was obtained as the crude extract.
The crude extract (containing pCocH3 or pCocH3-Fc)
prepared from leaves was used for the initial enzyme
activity assays (in triplicate).
Purification of the fusion protein pCocH3-Fc from the
crude extract was conducted by using Protein A Fast
Flow (GE Healthcare) affinity chromatography [24]. About
1 mL resin was first equilibrated with 20 CV (20 mL) of
PB buffer, loaded with crude extract (~200 mL per 1 mL
resin), and washed by 10–15 mL of PB buffer. Protein was
eluted by 10 mL of 50 mM sodium citrate buffer (pH 4.5),
and followed by another 10 mL of 50 mM sodium citrate
buffer (pH 3.8). Eluted protein solutions were neutralized
immediately with PB buffer and then concentrated by
Amicon centrifuge tubes (Millipore).
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Protein pCocH3 was not purified and CocH3 purified
from CHO-expression system was used [24] for comparison in the kinetic analysis.
Protein PEGylation

Protein conjugation with polyethylene glycol (PEG) polymer chains (PEGylation) was performed according to a
manufacture-provided protocol (JenKem Technology) in
order to extend the biological half-life of the protein.
Briefly, the purified pCocH3-Fc protein (1 μg/μL) was
quickly mixed with PEG 2000 at a ratio of 1:300 in
50 mM PB (pH 7.4), and incubated at 4 °C overnight. To
remove the remaining PEG, protein preparations were
filtered with Amicon Ultra-15 Centrifugal Filter Units
(Millipore) with abundant amount of 100 mM PB, and
finally concentrated to 500 μL.
In vitro enzyme activity assay

To monitor the protein expression, the catalytic activity
of the crude enzyme (pCocH3 or pCocH3-Fc) extract
against cocaine was assayed rapidly by using [3H](−)cocaine labeled on its benzene ring as described previously
[17]. Reaction mixture (200 μL) containing 10 μL of
enzyme solution, 50 μL of 400 nM cocaine containing
100 nCi [3H] -cocaine in 0.1 mM PB was incubated
at 25 °C for 3 min, and stopped by adding 200 μL of
0.05 M HCl which neutralizes the labeled benzoic
acid while ensuring a positive charge on the residual
cocaine. [3H]-labeled benzoic acid was extracted by 1 mL
of toluene and measured by scintillation counting.
The radiometric data were analyzed as described previously [28].
The final kinetic characterization of pCocH3-Fc against
cocaine was carried out on the purified pCocH3-Fc
with our previously established protocol using the
[3H](−)-cocaine [11, 24].
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Animals as adopted and promulgated by the National
Institutes of Health. The experimental protocol was
pre-approved by the IACUC (Institutional Animal Care
and Use Committee) at the University of Kentucky.
Enzyme administration

Mouse was placed in a small restraint (TV-150 STD,
Braintree Scientific, Inc., Braintree, MA) that left the tail
exposed. The tail was wiped with an alcohol pad, then a
1-ml syringe with a 30-gauge needle (Becton, Dickinson
and Company, Franklin Lakes, New Jersey) was used for
infusion via a tail vein. The intravenous (IV) injection
volume of the enzyme was controlled at 0.2 mL per 30 g
of mouse body weight.
Determination of the biological half-life in mice

Mice were injected IV (via the tail vein) with the enzyme
(pCocH3 or pCocH3-Fc or its PEGylated form, denoted
as PEG-pCocH3-Fc) in the dose of 0.075 mg/kg body
weight. First, the saphenous vein was punctured with a
needle. Approximately ~50 μL of blood sample was
collected into a capillary tube at various time points after
the enzyme injection. The blood samples were centrifuged at 5000 × g for 15 min. The isolated serum was
tested for the enzyme activity as described above. The
data for elimination of the enzyme from the circulation
were fitted to a double-exponential equation as described previously [4].
Protection experiment in mice

Mice were given 1 mg/kg pCocH3-Fc or saline intravenously (IV via tail vein), and then a lethal dose of cocaine
(180 mg/kg) intraperitoneally (IP). Each mouse was
monitored for its behavior and vitality for at least 1 h
post injection. Mice injected with saline solution and
cocaine were used as the negative control. Experiments
were done in triplicate (n = 3 for each group).

Subjects for in vivo activity tests

Results and discussion

Male CD1 mice (27–30 g) were obtained from Harlan
(Indianapolis, IN) and housed in groups of 4–5 mice per
cage. According to our previous experience, different
strains of mice are expected to show very similar results
for the effects of a given cocaine-metabolizing enzyme.
CD1 mice generally have very visible tail veins, which
makes the tail vein injection easier. For this reason, the
same type of mice were used in our previous in vivo
studies on the protein expressed in CHO cells [4]. All
mice were allowed ad libitum access to food and water
and were maintained on a 12-h light/dark cycle with
lights on at 8:00 AM in a room kept at a temperature of
21–22 °C. Each mouse was used only once. Experiments
were performed in the same colony room in accordance
with the Guide for the Care and Use of Laboratory

Expression of pCocH3-Fc

Expression constructs containing only a signal peptide
to target expression through the secretory pathway
(Fig. 1; pGWB1 and pGWBF1) did not result in any
detectable protein expression following vacuum infiltration for up to 11 days. However, expression of constructs
with ER-retention signal (Fig. 1; pGWB2 and pGWBF2)
resulted in detectable enzyme activity 4 and 5 days post
infiltration, suggesting that the protein expression was
dependent upon the ER-retention signal.
Then, we checked the expression level in the plant
leaves after the infiltration of agrobacteria by monitoring
the cocaine-hydrolyzing activity of the crude extract.
Both enzymes (pCocH3-Fc and pCocH3) were expressed
rapidly in plant cells, and peaked on Day 3 after
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Agrobacterium infiltration; then, the cocaine-hydrolyzing
activity in the plant leaves gradually went down.
Depicted in Fig. 2 is a typical pattern of the enzyme
expression in N. benthamiana leaves associated with
fusion construct pCocH3-Fc. These results suggested
that transient expression of the enzyme (pCocH3-Fc or
pCocH3) in the plant was quite rapid and efficient, and
that 3 days after bacteria infiltration should be the best
time to harvest leaves. Our results are remarkably different from the earlier observation that the expression of
human BChE or its mutant in N. benthamiana plant
started at an extremely low level (<1 mg/kg) within the
first eight (or more) days, but was able to continue and
reached a peak after 14–17 days post Agrobacterium infiltration [14]. The remarkably different protein expression patterns are likely due to the difference between the
vectors used. Specifically, the one used in the current
study is a traditional non-replication vector which starts
to diminish once it has entered plant leaves, whereas the
one used in the earlier study [14] is a viral vector (ICON
vector containing some viral functional components)
able to replicate in plant cells. The viral vector is also
able to communicate/travel between cells when a mobile
protein is expressed.
It is notable that, under the same experimental conditions, the expression level of Fc-fused protein pCocH3Fc was always higher than that of the corresponding
protein pCocH3 by about two-fold. After the harvest
time was determined to be 3 days, we further expressed
pCocH3-Fc and pCocH3 in N. benthamiana leaves for
multiple times. The replicate transient transfections

Fig. 2 Expression profiles of pCocH3 and pCocH3-Fc. For each
protein, three leaves per day were harvested from the same layer of
three independent plants on the indicated time, and mixed together
for enzyme extraction. The crude extracts prepared from leaves were
used for the initial enzyme activity assays (in triplicate). The protein
concentration was calculated based on the measured enzyme
activity (Vmax) and the known catalytic parameter (kcat = 5700 min−1)
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yielded between 2 and 4 mg/kg FW for pCocH3-Fc with
an average of ~3 mg/kg FW, while pCocH3 expression
ranged between 1 and 2 mg/kg FW with an average of
~1.5 mg/kg FW. So, the Fc fusion approximately doubled the pCocH3 expression in N. benthamiana leaves
under the same experimental conditions. For comparison, in our previous study [4] of the HSA-fused CocH1
(Albu-CocH1), the yield of the protein expression in the
CHO cells after the transient transfection was between 1
and 2 mg per liter (L) of culture medium with an
average of ~1.5 mg/L. So, the yield of the transient
expression of pCocH3 in the plant is comparable to that
of our previous transient expression of Albu-CocH1 in
CHO cells. The average yield of the transient expression
of pCocH3-Fc in N. benthamiana leaves is higher than
that of the transient expression of Albu-CocH1 in CHO
cells.
It should be pointed out that the average yield of
~3 mg/kg FW for pCocH3-Fc is still not high enough
for large-scale production at low cost. It is desirable to
have a yield of ~100 mg/kg FW (or more) feasible for
large-scale production at low cost. So, it might be necessary to improve the yield by ~30-fold.
In vitro activity of the purified enzyme

Fc fusion improved protein expression, but also facilitated protein purification. Very pure plant-expressed
CocH3-Fc (pCocH3-Fc) protein (see Fig. 3) was obtained
by using the convenient protein A affinity chromatography. However, purification of the unfused enzymes,
such as wild-type pBChE, must undergo multiple steps
of various chromatography [8, 14]. In this study, we
purified Fc-fused CocH3, i.e. pCocH3-Fc, by using a
one-step affinity chromatography, determined its steadystate kinetics against cocaine and compared it with
CHO-expressed CocH3. According to the data depicted
in Fig. 3a, we observed that KM = 3.0 μM and kcat =

Fig. 3 Kinetic and electrophoresis analyses of pCocH3-Fc and CHO
cells-expressed CocH3-Fc. a In vitro kinetic profile of pCocH3-Fc and
CocH3-Fc. The assays were carried out in triplicate. b SDS-PAGE in
which lane M is associated with protein marker, lane 1 with
CocH3-Fc expressed in CHO cells, and lane 2 with pCocH3-Fc
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5770 min−1 for pCocH3-Fc against cocaine; we did not
note any significant change in the enzyme activity after
the PEGylation (data not shown). In comparison, CHO
cells-derived CocH3 showed a KM of 3.1 μM and a kcat
of 5700 min−1, suggesting that pCocH3-Fc exhibited a
similar catalytic activity against cocaine. These in vitro
activity data are also similar to the earlier observation
reported by Dr. Mor et al. [8] for the un-fused BChE
mutant expressed in plant.
On the other hand, the SDS-PAGE data of the purified
proteins also revealed that the pCocH3-Fc protein
expressed in N. benthamiana leaves had a molecular
weight significantly smaller than CocH3-Fc expressed in
the CHO cells, as shown in Fig. 3b. The difference in
molecular weight corresponds to the difference in glycosylation between the CHO and plant expression systems
(no determination of glycosylation was made or reported
in the paper). As well known, BChE from human plasma
is a highly glycosylated protein, and each BChE molecule
contains nine sugar chains which accounts for about
24 % of its total molecular weight [16]. The underglycosylated BChE from an expression system other than
mammalian cells was often a major hurdle for establishing a successful expression system of this enzyme, such
as goat milk, insect cell and plant cell [1, 8, 12]. The
under-glycosylation is expected to affect the pharmacokinetic profile of the protein, although it did not affect
the in vitro enzyme activity.

Biological half-life of pCocH3-Fc in mice

The purified enzymes including pCocH3-Fc and the
PEGylated pCocH3-Fc (denoted as PEG-pCocH3-Fc)
were tested for their pharmacokinetic profiles in mice.
Mice were administered IV with the purified enzyme
(0.075 mg/kg). The blood was sampled at 2, 15, and
30 min, and 1, 2, 4, 8, 12, 24, and 48 h after the enzyme
administration. Depicted in Fig. 4a are the time courses
of the active enzyme (pCocH3-Fc or PEG-pCocH3-Fc or
pCocH3) concentrations remained after the IV administration of the enzyme materials. The time-course of
pCocH3 was determined by IV administration of the
crude extract of pCocH3. For each enzyme sample, the
enzyme concentrations ([E]) in the collected plasma
samples were analyzed by detecting the enzyme activity
(Vmax) of the plasma, resulting in [E] = Vmax/kcat. The
same kcat value (5700 min−1) was used for standardizing
across samples.
The measured time-dependent concentrations of the
active enzymes were fitted to a well-known double exponential equation ( ½E t ¼ Ae−k 1 t þ Be−k 2 t ) which accounts
for both the enzyme distribution process (the fast phase,
associated with k1) and elimination process (the slow
phase, associated with k2). The half-life associated with

Fig. 4 In vivo profiles of pCocH3-Fc. a Time-dependent concentrations
of the active enzyme pCocH3-Fc or PEG-pCocH3-Fc (PEGylated
pCocH3-Fc) in the plasma of mice after IV administration of
the enzyme (0.075 mg/kg) determined in triplicate. b Lethality
of 180 mg/kg cocaine (IP) with or without pretreatment of
1 mg/kg pCocH3-Fc. The lethality tests were performed in
triplicate (n = 3 for each group). For the mice survived from the acute
cocaine toxicity testing, the observation of animal behaviors was kept
for at least 1 h to make sure that they continued to behave normally
after the survival

the enzyme elimination rate constant k2 is called the
biological half-life t1/2 (the usually referred in vivo halflife). Thus, we obtained t1/2 = ~25 min for pCocH3-Fc
and ~12 h for PEG-pCocH3-Fc, as depicted in Fig. 4.
The biological half-life of pCocH3-Fc was only slightly
longer than that (~13 min) of pCocH3 in mice.
In vivo activity for cocaine detoxification

We further examined the potential therapeutic value of
pCocH3-Fc by using an in vivo protection model [28]
used previously for CocH3 expressed in mammalian
cells. Specifically, we wanted to know whether pCocH3Fc can effectively protect mice from the acute toxicity of
a lethal dose of cocaine (180 mg/kg, LD100), because
pretreatment with ~1 mg/kg CocH3 expressed in
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mammalian cells at 1 min before the cocaine injection
fully protected the mice from such a lethal dose of
cocaine [25, 28]. For the mice survived from the acute
cocaine toxicity testing, the observation of animal behaviors was kept for at least 1 h to make sure that they
continued to behave normally after the survival. As
shown in Fig. 4b, for the negative control experiments
(saline) without administration of the enzyme, IP injection of 180 mg/kg produced lethality in all mice tested.
Pretreatment with 1 mg/kg pCocH3-Fc at 1 min before
cocaine injection provided full protection in mice after
receiving a lethal dose of cocaine (180 mg/kg, IP). So,
the plant-expressed pCocH3-Fc was indeed active in vivo
for cocaine detoxification.

Conclusions
This is the first report on plant expression of the Fc
fusion protein form of a cocaine hydrolase or BChE or
BChE mutant, with the goal to know whether the
promising CocH3-Fc can be expressed in a plant in any
yield. The vector used in the present study might not be
advanced enough, but it has been demonstrated that the
active pCocH3-Fc enzyme can be expressed in plant N.
benthamiana leaves with an average yield of ~3 mg/kg
(compared to the average yield of ~1.5 mg/kg FW for
the transient expression of pCocH3 in N. benthamiana
leaves and the average yield of ~1.5 mg/L for the transient expression of Albu-CocH1 in CHO cells), and that
the plant-expressed enzyme (pCocH3-Fc) was as active
as the same enzyme (CocH3-Fc) expressed previously in
CHO cells. In addition, the Fc fusion increased the yield
of the enzyme expression in plant under the same
experimental conditions, and greatly simplified purification procedure of the enzyme. But it might be necessary
to further improve the yield by ~30-fold before the plant
protein expression is feasible for large-scale production
at low cost.
Further, it has been known that CocH3-Fc expressed
in CHO cells has a considerably prolonged biological
half-life than CocH3 expressed in CHO cells [4]. However, when the proteins were expressed in the plant, the
biological half-life of pCocH3-Fc in mice was as short as
that of pCocH3. Combination of the results obtained
from the present study and the earlier studies showing a
considerably improved biological half-life of the plantexpressed BChE [19] suggests that the in planta protein
sialylation is essential for protein pBChE or pBChE
mutant to have a long biological half-life, whether the
protein is fused with Fc or not. In lack of the in planta
protein sialylation in the present study, the Fc fusion did
not prolong the biological half-life of the enzyme
pCocH3 at all. Hence, further development for the Fc
fusion protein production in plant should utilize a more
advanced vector with additional genes required for the
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in planta protein sialylation [19]. It is expected that
utilization of the more advanced vector would enable to
more efficiently produce pCocH3-Fc with the overall
glycosylation profile resembling the plasma-derived
orthologue. The pCocH3-Fc protein with an improved
glycosylation profile is expected to have a much longer
biological half-life. Additional genes and proper promoters should also be included in the vector for a higher
yield of the enzyme expression.
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